<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> is a multisystemic <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disorder</z:e> caused mainly by mutations in the fibrillin-1 gene </plain></SENT>
<SENT sid="1" pm="."><plain>The entire cardiovascular system is affected in patients with <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0002616'>Aortic root dilatation</z:hpo>, <z:hpo ids='HP_0001659'>aortic valve regurgitation</z:hpo> or - the most feared and life-threatening symptom - <z:e sem="disease" ids="C0340646" disease_type="Disease or Syndrome" abbrv="">aortic root dissection</z:e> are the most common manifestations </plain></SENT>
<SENT sid="3" pm="."><plain>Therapeutic strategies, such as prophylactic aortic root surgery and pharmacological therapy, focus on the prevention of <z:hpo ids='HP_0002647'>aortic dissection</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Currently, the standard medicinal treatments targeting <z:hpo ids='HP_0001724'>aortic dilatation</z:hpo> and dissection consist of agents generally used to lower blood pressure and/or the inotropic state of the heart </plain></SENT>
<SENT sid="5" pm="."><plain>By these means, the cyclic repetitive forces exerted on the aortic wall are diminished and thus the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0001724'>aortic dilatation</z:hpo> is potentially prevented </plain></SENT>
<SENT sid="6" pm="."><plain>Although these pharmacological agents may offer some benefit in reduction of <z:hpo ids='HP_0004942'>aortic aneurysm</z:hpo> expansion rate, they do not target the underlying cause of the progressive aortic degradation </plain></SENT>
<SENT sid="7" pm="."><plain>AREAS COVERED: This review discusses the effectiveness of frequently prescribed medications used to prevent and delay aortic complications in <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>New insights on the biochemical pathways leading to <z:e sem="disease" ids="C0003493" disease_type="Disease or Syndrome" abbrv="">aortic disease</z:e> are also discussed to highlight new targets for pharmacological therapy </plain></SENT>
<SENT sid="9" pm="."><plain>EXPERT OPINION: Recent insights in the transforming growth factor beta signaling pathway and inflammatory mechanisms in a well-established mouse model of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e>, have led to studies exploring new pharmacological treatment strategies with <z:chebi fb="1" ids="50845">doxycycline</z:chebi>, <z:chebi fb="0" ids="35664">statins</z:chebi> and <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor blockers </plain></SENT>
<SENT sid="10" pm="."><plain>Pharmacological therapy is focused more on prevention than on delay of aortic wall pathology in <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Of the new pharmacological treatment strategies targeting aortic pathology in <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e>, angiotensin receptor type 1 blockers are promising candidates, with several clinical trials currently ongoing </plain></SENT>
</text></document>